β Boswellic Acid Blocks Articular Innate Immune Responses: An In Silico and In Vitro Approach to Traditional Medicine

Area of Science:

• Rheumatology and immunology
• Computational pharmacology
• Molecular biology

Background:

• Osteoarthritis (OA) is a progressive rheumatic disease characterized by cartilage degradation, synovial inflammation, and bone destruction, driven by inflammatory factors like IL6, TNFα, and COX2.
• Currently, no definitive clinical treatments exist for OA.
• Traditional Ayurvedic medicine utilizes *Boswellia serrata* extracts (BSE) for rheumatic conditions, but specific components lack clinical approval, despite recent evidence of β boswellic acid (BBA) reducing OA cartilage loss.

Purpose of the Study:

• To elucidate the therapeutic mechanism of β boswellic acid (BBA) in osteoarthritis (OA) using a multi-omics approach.
• To provide evidence for BBA's potential as a therapeutic agent for OA by investigating its effects on innate immune pathways in joint cells.

Main Methods:

• Computational pharmacology, proteomics, transcriptomics, and metabolomics were employed to analyze BBA's effects.
• Experiments were conducted on mouse and primary human OA joint cells, including chondrocytes, osteoblasts, and synoviocytes.
• Key signaling pathways, including TLR4, IL1R, ROS, MAPK p38/NFκB, NLRP3, IFNαβ, TNF, and ECM-related pathways, were assessed.

Main Results:

• Beta boswellic acid (BBA) was found to bind to the Toll-like Receptor 4 (TLR4) complex.
• BBA effectively inhibits both TLR4 and Interleukin 1 Receptor (IL1R) signaling pathways in OA chondrocytes, osteoblasts, and synoviocytes.
• Inhibition of these pathways led to downregulated reactive oxygen species (ROS) synthesis and suppressed inflammatory and ECM-related signaling cascades.

Conclusions:

• Beta boswellic acid (BBA) demonstrates significant therapeutic potential by blocking innate immune responses central to osteoarthritis pathophysiology.
• BBA's mechanism involves the inhibition of TLR4 and IL1R signaling, reducing downstream inflammatory mediators and pathways.
• These findings strongly support the potential clinical application of BBA as a dietary supplement or therapeutic agent for osteoarthritis, pending further clinical evaluation.